An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Tumor Biology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13277-012-0626-6PMID 23269606
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy

  2012cited by this paper
• Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer

  2012cited by this paper
• The treatment of severe hepatitis B virus reactivation after chemotherapy

  2012cited by this paper
• A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?

  2011cited by this paper
• Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma

  2010cited by this paper
• Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

  2010cited by this paper
• Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies Treated with Chemotherapy

  2010cited by this paper
• Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin’s lymphoma in Hokkaido

  2009cited by this paper
• Chronic hepatitis B: Update 2009

  2009cited by this paper
• A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial

  2008cited by this paper
• The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma

  2008cited by this paper
• Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta‐analysis

  2007cited by this paper
• Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management

  2007cited by this paper
• The relationship of hepatitis B virus infection and non‐Hodgkin’s lymphoma and its impact on clinical characteristics and prognosis

  2007cited by this paper
• Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation‐related mortality in chemotherapy patients: a meta‐analysis

  2007cited by this paper
• Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma

  2006cited by this paper
• Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.

  2006cited by this paper
• Prevention of Hepatitis B Virus Reactivation in Patients With Nasopharyngeal Carcinoma With Lamivudine

  2005cited by this paper
• Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin’s lymphoma

  2004cited by this paper
• Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP

  2004cited by this paper
• Lamivudine prophylaxis for prevention of chemotherapy‐induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

  2004cited by this paper
• Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients

  2004cited by this paper
• Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

  2004cited by this paper
• Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy

  2004cited by this paper
• Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration

  2004cited by this paper
• The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.

  2003cited by this paper
• Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

  2003cited by this paper
• Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.

  2002cited by this paper
• Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.

  2002cited by this paper
• Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

  2002cited by this paper
• High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation.

  2002cited by this paper
• [Chronic hepatitis B].

  2001cited by this paper
• Chronic hepatitis B

  2001cited by this paper
• Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy

  2001cited by this paper
• Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.

  1999cited by this paper

• Lamivudine/rituximab

  2023cites this paper
• 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

  2019cites this paper
• 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

  2019cites this paper
• Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin

  2018cites this paper
• Induction Chemotherapy Has No Prognostic Value in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Chronic Hepatitis B Infection in the IMRT Era

  2017cites this paper
• Efficacy and safety analysis of rituximab combined with chemotherapy in the treatment of B-cell lymphoma patients complicated with hepatitis B virus infection.

  2016cites this paper
• Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization.

  2016cites this paper
• 2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

  2015cites this paper
• 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma

  2015cites this paper
• Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients.

  2014cites this paper
• Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinonma Patients

  2014cites this paper
• Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: Analysis of 1301 patients from an endemic area in China

  2014cites this paper